A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Not yet recruitingOBSERVATIONAL

Enrollment

800

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2031

Study Completion Date

November 30, 2031

Conditions

EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases

Interventions

DRUG

zorifertinib

Cohort A and B will receive zorifertinib as first line treatment

All Listed Sponsors

lead

Alpha Biopharma (Jiangsu) Co., Ltd.

INDUSTRY